Dr. Chulgi Min · Chief Technology Officer (CTO), Research Institute
Dr. Min holds a Ph.D. in Pharmacology from Cornell University and served as a professor in the Department of Life Sciences at Ajou University for approximately 29 years. Spanning genetic engineering, protein engineering, and bioinformatics, he has focused on stem cell-based treatment of intractable diseases, and currently serves as Chief Technology Officer (CTO) of OCELLBIO's research institute.
- B.S. and M.S. from Seoul National University; Ph.D. in Pharmacology from Cornell University (1991)
- Postdoctoral Researcher, Caltech, USA (1991–1993)
- Professor, Department of Life Sciences, Ajou University, for approximately 29 years
- Research Fields: Genetic Engineering, Protein Engineering, Bioinformatics
- Holder of numerous patents, including RGMc-based stem cell induction media
Dr. Haegwon Kim · Research Advisor
Dr. Kim earned a Ph.D. in Zoology from Seoul National University and conducted postdoctoral research at the UK Medical Research Council (MRC) and Johns Hopkins University in the United States. He served as a professor in the Department of Life and Environmental Sciences and as Dean of the College of Natural Sciences at Seoul Women's University, and currently serves as an advisor to OCELLBIO's research institute.
- B.S., M.S., and Ph.D. in Zoology from Seoul National University
- Postdoctoral Research, UK Medical Research Council (MRC) and Johns Hopkins University, USA
- Former Dean, College of Natural Sciences, Seoul Women's University
- President, Korean Society for Reproductive Medicine
- Editorial Board Member, World Journal of Stem Cells (2009–2013)
- Primary Research Fields: Cell Therapeutics, Stem Cell Differentiation
A Research Philosophy Grounded in Convergence Technology
The research team's patent portfolio is the fruit of long-standing academic rigor, and the result of integrating cutting-edge convergence technologies such as protein engineering and bioinformatics.
- Mitochondrial & Telomere Protection: Suppressing cellular aging and maximizing energy metabolism efficiency
- Proprietary Induction Medium (RGMc): High-efficacy stem cell induction technology
- RNA/PNA Delivery System: Next-generation nucleic acid platform technology
- Neurology: Differentiation technology applied to Parkinson's disease and Alzheimer's disease
- Metabolism: Induction of insulin-secreting cells for diabetes treatment
The content on this website is intended to introduce OCELLBIO's business. Some facilities and certifications are currently being built or are in progress. Specific terms of cooperation will be provided upon separate inquiry.